BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 19841288)

  • 1. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
    Mihailidou AS; Loan Le TY; Mardini M; Funder JW
    Hypertension; 2009 Dec; 54(6):1306-12. PubMed ID: 19841288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
    Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
    Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
    Marques-Neto SR; Ferraz EB; Rodrigues DC; Njaine B; Rondinelli E; Campos de Carvalho AC; Nascimento JH
    Cardiovasc Drugs Ther; 2014 Apr; 28(2):125-35. PubMed ID: 24258356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?
    Chai W; Hofland J; Jansen PM; Garrelds IM; de Vries R; van den Bogaerdt AJ; Feelders RA; de Jong FH; Danser AH
    J Hypertens; 2010 May; 28(5):1044-53. PubMed ID: 20179635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of mineralocorticoid and glucocorticoid receptors to the chronotropic and hypertrophic actions of aldosterone in neonatal rat ventricular myocytes.
    Rossier MF; Python M; Maturana AD
    Endocrinology; 2010 Jun; 151(6):2777-87. PubMed ID: 20392829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner.
    Bunda S; Liu P; Wang Y; Liu K; Hinek A
    Am J Pathol; 2007 Sep; 171(3):809-19. PubMed ID: 17724138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid receptor mediated the propofol self-administration by dopamine D1 receptor in nucleus accumbens.
    Wu B; Liang Y; Dong Z; Chen Z; Zhang G; Lin W; Wang S; Wang B; Ge RS; Lian Q
    Neuroscience; 2016 Jul; 328():184-93. PubMed ID: 27126557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured gill epithelium.
    Kelly SP; Chasiotis H
    J Exp Biol; 2011 Jul; 214(Pt 14):2308-18. PubMed ID: 21697422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
    Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
    Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
    Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
    Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cardioprotective effects of mineralocorticoid receptor antagonists.
    van den Berg TN; Rongen GA; Fröhlich GM; Deinum J; Hausenloy DJ; Riksen NP
    Pharmacol Ther; 2014 Apr; 142(1):72-87. PubMed ID: 24275323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury.
    Ashton AW; Le TY; Gomez-Sanchez CE; Morel-Kopp MC; McWhinney B; Hudson A; Mihailidou AS
    Mol Endocrinol; 2015 Aug; 29(8):1144-55. PubMed ID: 26121234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid receptor but not mineralocorticoid receptor mediates the activation of ERK pathway and CREB during morphine withdrawal.
    Navarro-Zaragoza J; Laorden ML; Milanés MV
    Addict Biol; 2017 Mar; 22(2):342-353. PubMed ID: 26598419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat.
    McCullers DL; Sullivan PG; Scheff SW; Herman JP
    Neuroscience; 2002; 109(2):219-30. PubMed ID: 11801359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
    Chai W; Garrelds IM; de Vries R; Danser AH
    Hypertension; 2006 Apr; 47(4):665-70. PubMed ID: 16490840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: receptor measures and functional studies.
    Kim PJ; Cole MA; Kalman BA; Spencer RL
    J Steroid Biochem Mol Biol; 1998 Nov; 67(3):213-22. PubMed ID: 9879980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
    Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
    Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
    Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.